ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Underdosed Edoxaban and Clinical Outcomes in Patients with Non-valvular Atrial Fibrillation in Real World: A Retrospective Cohort Study.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundUnderdosed edoxaban was prevalent in Asian clinical practice, yet its outcomes in patients with non-valvular atrial fibrillation (AF) remain unclear.MethodsWe conducted a retrospective cohort study at a Chinese tertiary-care hospital to investigate the real-world effectiveness and safety of underdosed edoxaban in patients with AF. According to international dosing criteria, patients were stratified into recommended dose group and under dosed group. After inverse probability of treatment weighting, the effectiveness endpoints (ischemic stroke (IS) or systemic embolism (SE), all-cause mortality) and safety endpoints (major bleeding and clinically relevant non-major [CRNM] bleeding) were evaluated between the two groups.ResultsOf 616 included non-valvular AF patients, 31.5% received an underdosed edoxaban regimen. The under dosed group showed no significant differences in the risk of IS or SE (HR 0.78, 95%CI 0.18-3.32), major bleeding (HR 0.19, 95%CI 0.01-2.12), or all-cause mortality (HR 0.60, 95%CI 0.28-1.31) compared to the recommended dose group. However, a significant reduction in CRNM bleeding was observed in the under dosed group (HR 0.47, 95%CI 0.23-0.95).ConclusionIn this real-world Chinese tertiary-care cohort, underdosed edoxaban was administered to nearly one-third of patients with non-valvular AF. Compared with the recommended dose, this dosing strategy was associated with comparable risks of IS/SE and major bleeding, as well as a potentially lower incidence of CRNM bleeding. These findings should be considered preliminary and warrant validation in larger, multi-center prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.